Oncology’s Number One Journal: Oncotarget

D3
December 25, 2016

Since 2010, the online multi-disciplinary journal, “Oncotarget”, has published papers in weekly issues concerning all areas of oncology. The Editors-in-Chief, Andrei V. Gudkove from Park Cancer Institute in Buffalo, New York; and Mikhail V. Blagosklonny from Roswell Park Cancer Institute in Buffalo, New York, have successfully accomplished their mission. Clearly defined on the website, its mission is to make scientific results available quickly and to anyone, to maximize the impact of research through insightful reviews, to allow exceptional discoveries available immediately, to eliminate borders between specialties, to link different fields of biomedical science, and to foster applications of basic and clinical science to fight disease. The ultimate goal is to eliminate disease. The editorial board of Oncotarget consists of about 50 prominent scientists from many of the major universities, cancer centers, and medical schools in the United States and overseas. Following the COPE Code of Conduct and Best Practice Guidelines for Journal Editors and the Code of Conduct for Journal Publishers, hundreds of articles appear in the journal along with interviews of prominent scientists in video clips. Due to its success, the journal is now launching other sections, including Gerotarget/Aging, Immunology/Microbiology, Neuropathology/Neuroscience, Endocrinology, Cardiology, Metabolism, Cell & Mol Biology, and Pharmacology. Source: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=718&path[]=1089

The archives of Oncotarget are easily accessible from the menu on the left-hand side of the page and includes every issue as it appeared originally. For example, Volume 7, No. 46 Table of Contents includes:

Priority Research Papers
Research Papers: Aging
Research Papers: Pathology
Research Papers: Immunology
Research Papers: Autophagy and Cell Death
Clinical Research Papers
Reviews

Read more:
@oncotargetjrnl
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Every article’s title, authors and their affiliation, supplementary information, and abstract are available to view as a PDF or HTML. Headings within each article include results, discussion, methods and materials, acknowledgement and grant support, conflicts of interest, and references. There is also the capability of ordering a reprint.

Review a publishing via Oncotarget on Impact Journals

Leave a Reply

Your email address will not be published. Required fields are marked *